Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Google Secures Pentagon AI Deal for Classified Projects 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
SAN DIEGO, Feb. 08, 2016 -- SENTÉ, a privately held specialty aesthetics company pioneering the development of differentiated medical grade skincare products based on the science of glycosaminoglycans, today announced the close of a $5 million financing. This financing included both existing and new individual investors and provides SENTÉ with a sizable cash balance to fuel expansion and continued company growth.
“We are very pleased to continue seeing such strong investor interest in our company from leading experts in the healthcare and aesthetic field,” said Kleanthis G. Xanthopoulos, Ph.D., SENTÉ Co-Founder and Board Member. “Our investors share our vision in creating unique science based dermatological products that will have profound impacts on the skin, and we very much look forward to continued growth in this endeavor."
The Company, which realized top line year over year growth of 266%, will use this financing to increase its domestic sales force, support the launch of new and innovative products, pursue international expansion and invest behind meaningful new technologies.
“We are excited about the significant progress SENTÉ made in 2015 and we are equally pleased with the continued financial support of our investors,” said Faheem Hasnain, Chairman of the Board of SENTÉ. “We look forward to an exciting year in 2016 with continued strong revenue growth.”
About SENTÉ:
SENTÉ is a privately held specialty aesthetics company leveraging its expertise and foundation in biotechnology to deliver novel, science-based skin care products. SENTÉ is a recognized leader in the development of innovative and targeted medical skincare products based on glycosaminoglycans. Founded in 2007 and based in San Diego, California, further information may be found at http://sentelabs.com/. SENTÉ products are available through our exclusive network of physicians and medically supervised spas.
Financial Contact: Michael Brower Chief Financial Officer [email protected] p: 760.478.3603 Media Contact: Creative Media Marketing Danielle Hale [email protected] p: 212.979.8884 ext. 213
